Aevi Posts Financial Results for Q1 2017

Genetics Investing

Aevi Genomic Medicine released the company’s financial results for the first quarter of 2017 and announced it will be moving forward with a Phase 2 clinical trial of AEVI-001.

Aevi Genomic Medicine (NASDAQ:GNMX) released the company’s financial results for the first quarter of 2017 and announced it will be moving forward with a Phase 2 clinical trial of AEVI-001.
As quoted in the press release:

“Following additional analysis of the SAGA trial, we remain positive about the genetic subset of patients identified that demonstrate a clear and statistically significant response to AEVI-001,” said Mike Cola, CEO of Aevi Genomic Medicine. “This discovery will allow us to move forward with the development of AEVI-001 in ADHD, and potentially other neurodevelopmental disorders in the future, including Autism Spectrum Disorder. We look forward to initiating the Phase 2 trial of AEVI-001 in patients with the identified genetic subset during the second half of 2017 and anticipate announcing top-line data in mid-2018.”

Click here to read the full press release.

Source: www.newswire.ca

The Conversation (0)
×